+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems

  • ID: 5117718
  • Book
  • August 2020
  • Elsevier Science and Technology

Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models.

The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown

1. Chronic respiratory diseases: An introduction and need for novel drug delivery approaches 2. Drug delivery of respiratory medicines in practice 3. Advanced drug delivery systems for respiratory diseases 4. Novel drug delivery systems and significance in respiratory diseases 5. Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis 6. Targeting biofilms in chronic respiratory infections using drug delivery systems 7. Absorption enhancement of macromolecule administered intrapulmonary 8. In silico analysis of drug delivery in respiratory disease 9. Concepts of nanotechnology in nanomedicine: From discovery to applications 10. Advancement in translational respiratory research using nanotechnology 11. Nanoparticle-based macromolecule drug delivery to lungs 12. Formulation and role of polymeric and inorganic nanoparticles in respiratory diseases 13. Inhalable hybrid nanocarriers for respiratory disorders 14. Functionalized nanoparticles in pulmonary disease diagnosis 15. Drug delivery system in pulmonary disease: Role of microparticles 16. Microparticulate drug delivery systems for targeting respiratory diseases 17. Porous particulate platforms for enhanced pulmonary delivery of bioactives 18. Liposomes in the treatment of chronic respiratory conditions 19. Theranostic drug delivery systems for targeted therapy of lung diseases 20. Targeted polymeric miceller systems for respiratory diseases 21. Hydrogels for pulmonary drug delivery 22. Mucoadhesive drug delivery systems in respiratory diseases 23. Targeting lung cancer using advanced drug delivery systems 24. Plant-based drug delivery systems in respiratory diseases 25. Role of essential oils in respiratory diseases through advanced and nanodrug delivery systems 26. Pharmacokinetics and pharmacodynamics of the advanced drug delivery systems

Note: Product cover images may vary from those shown
Kamal Dua Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Kamal Dua is a Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), has a research experience of over 12 years working in the field of drug delivery targeting inflammatory diseases and cancer. Dr. Dua is also a node leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step toward translation into clinics. Dr. Dua researches in two
complementary areas: drug delivery and immunology, specifically addressing how these disciplines can advance one another helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua's research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. Dr. Dua is also an adjunct assistant professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada; Adjunct Fellow
with the NICM Health Research Institute at Western Sydney University, Australia and Honorary Research Associate with the Australia-China Relations Institute (UTS:ACRI) and Consultant at ULTI Pharmaceuticals. He also held a Conjoint Lecturer position with the School of Biomedical Sciences and Pharmacy, The University of Newcastle, Australia. He has also published more than 80 research articles in the peerreviewed international journals and authored or coauthored four books and various book chapters.
Philip M. Hansbro Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, NSW, Australia.

Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science,
Sydney, NSW, Australia
Ridhima Wadhwa Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Australia
Mehra Haghi Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Australia
Lisa G. Pont Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Lisa G. Pont is a Professor in the Discipline of Pharmacy, Graduate School of Health at the University of Technology Sydney. Pont is a pharmacoepidemiologist with expertise in medicine utilization and health service research to evaluate, understand, and improve the quality and safety of medicine use in practice. Her research explores current practices and patterns of medicines use across populations with a focus on the safety and quality of prescribing and medicines use. Throughout her career, Professor Pont has received a number of awards including two national NPS MedicineWise awards in 2014 and in 2016 for her research. She is a registered pharmacist and was awarded the Society of Hospital Pharmacist of Australia Medal of Merit in 2018.
Kylie A. Williams Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.

Kylie A. Williams is a pharmacist and academic leader. She is a founding member of the Graduate School of Health at University of Technology Sydney (UTS), where she is currently the Head of Pharmacy and the Deputy Head of School Learning & Teaching. She has over 25 years of academic experience in learning and teaching, curricula development, research, and academic leadership. Professor Williams leads a research team focused on development, implementation, and evaluation of new models of pharmacy and health service delivery. Alongside her research expertise, Professor Williams is internationally recognized for her curriculum development, and has received a number of teaching grants and awards and has coauthored numerous teaching-related peer-reviewed journal articles, professional books, and educational articles for pharmacists.
Note: Product cover images may vary from those shown
Adroll
adroll